Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio Q3 Revenue Up 53% to $48.7M; $1.0B Nine-Month Loss Is Mostly Non-Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.09
Mkt Cap
$9.152B
52W Low
$1.95
52W High
$12.43
52W Position info
315% above low
Off High info
35% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.95.

Summary

ImmunityBio reported Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, with $334.3 million in cash and securities. The $1.0 billion nine-month net loss was driven mainly by a $749.7 million non-cash fair value charge, not operations.


Key Events · Earnings and Guidance · IBRX

  • Q3 Revenue Grows 53% to $48.7M

    Net product revenue reached $48.7 million in Q3 2026 versus $31.8 million a year earlier, and $143.6 million for the first nine months, up 92% from $74.7 million.

  • $1.0B Loss Is Mostly Non-Cash

    The nine-month net loss of $1.0 billion includes a $749.7 million non-cash change in fair value of the related-party convertible note and warrant/derivative liabilities; adjusted net loss was $265.2 million.

  • $334.3M Cash Funds BCG-Naïve sBLA

    Cash, cash equivalents and marketable securities totaled $334.3 million at September 30, 2026, with the BCG-naïve NMIBC sBLA submission targeted for Q4 2026.

  • Balance Sheet Still Levered

    Total liabilities of $1.75 billion, including an $834.9 million related-party convertible note at fair value and a $426.3 million revenue interest liability, leave a $1.15 billion stockholders' deficit.


Analysis · IBRX · Life Sciences

Revenue is compounding fast — $48.7 million in Q3 and $143.6 million for nine months, up 92% — and the $334.3 million cash pile funds the BCG-naïve sBLA submission targeted for Q4 2026. The headline $1.0 billion nine-month loss is almost entirely accounting: a $749.7 million non-cash fair value charge on the related-party convertible note and warrant/derivative liabilities, driven by the rising share price, not by cash leaving the business. The real operating number is the $265.2 million adjusted net loss, and the real balance-sheet fact is a $1.15 billion stockholders' deficit against $1.75 billion of liabilities, which keeps the company dependent on continued financing.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IBRX was trading at $8.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $7.52 info
Change: -$0.070 (-0.92%) info
Market Cap: $9.152B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $7.52 info
Change: -$1.32 (-15%) info
Market Cap: $9.152B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $7.52 info
Change: -$1.24 (-14%) info
Market Cap: $9.152B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $7.52 info
Change: -$1.90 (-20%) info
Market Cap: $9.152B info
IBRX
Oct 14, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $9.74
Real-time Price: $7.52 info
Change: -$2.22 (-23%) info
Market Cap: $9.152B info